Alexza's Schizophrenia Score (ALXA)

Posted in pre-market 
September 3rd, 2008

Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) announced positive results from a clinical trial of its Staccato drug in schizophrenic patients with acute agitation. Shares are indicated up almost 10% on first look this morning, although no trading has been seen.

Average daily volume in this issue is only about 115,000 shares.  Its 52-week trading range is $3.75 to $9.72.

Jon C. Ogg
September 3, 2008

Comments are closed